专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09242946B2 High purity diaminophenothiazinium compounds including methylthioninium chloride (MTC) 有权
标题翻译：高纯度二氨基吩噻嗪鎓化合物，包括甲基硫堇（MTC）
公开(公告)号：US09242946B2
公开(公告)日：2016-01-26
申请号：US12875465
申请日：2010-09-03
申请人： John Mervyn David Storey , James Peter Sinclair , Colin Marshall , Han Wan Tan , Claude Michel Wischik
发明人： John Mervyn David Storey , James Peter Sinclair , Colin Marshall , Han Wan Tan , Claude Michel Wischik
IPC分类号： C07D279/18 , C09B19/02
CPC分类号： A61K31/5415 , A61K9/0019 , A61K49/006 , C07D279/18 , C09B19/02 , G01N33/52 , Y02A50/393
摘要： This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methylhioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.
摘要翻译：本发明一般涉及化学合成和纯化领域，更具体地涉及合成和纯化某些3,7-二氨基 - 吩噻嗪-5-鎓化合物（本文称为“二氨基吩噻嗪鎓化合物”）的方法，包括甲基氯化铑（MTC）（也称为亚甲基蓝）。在一个实施方案中，该方法包括以下步骤：按顺序：亚硝基化（NOS）; 亚硝酰还原（NR）; 硫代磺酸形成（TSAF）; 氧化偶合（OC）; Cr（VI）还原（CR）; 两性离子中间体（IAPOZI）的分离和纯化; 闭环（RC）; 氯化物盐形成（CSF）; 一种：硫化物处理（ST）; 二甲基二硫代氨基甲酸酯处理（DT）; 碳酸盐处理（CT）; 乙二胺四乙酸处理（EDTAT）; 有机萃取（OE）; 和重结晶（RX）。本发明还涉及所得的（高纯度）化合物，包含它们的组合物（例如片剂，胶囊）及其在灭活病原体的方法中的用途，以及治疗和诊断方法等，例如对于tau蛋白病，阿尔茨海默病（AD），皮肤癌，黑素瘤，病毒性疾病，细菌性疾病或原生动物疾病。

2. 发明申请

US20110300074A1 3,6-DISUBSTITUTED XANTHYLIUM SALTS 有权
标题翻译： 3,6-取代的XANTHYLIUM SALTS
公开(公告)号：US20110300074A1
公开(公告)日：2011-12-08
申请号：US13133868
申请日：2009-12-10
申请人： Scott Clunas , John Mervyn David Storey , Janet Elizabeth Rickard , David Horsley , Charles Robert Harrington , Claude Michel Wischik
发明人： Scott Clunas , John Mervyn David Storey , Janet Elizabeth Rickard , David Horsley , Charles Robert Harrington , Claude Michel Wischik
IPC分类号： A61K49/00 , A61K31/352 , A61K31/5377 , A61K31/4545 , A61K31/4025 , A61K31/382 , A61K31/498 , A61K31/538 , A61P25/28 , A61P25/16 , A61P25/00 , C07K14/00 , G01N33/566 , C07D491/22 , C07D311/82 , C07D335/10 , C07D413/14 , C07D405/14 , C07D241/46 , C07D265/38 , C07D493/16 , G01N33/53 , A61K31/4375
CPC分类号： C07D311/82 , A61K9/0053 , A61K31/352 , A61K31/382 , A61K31/4025 , A61K31/4545 , A61K31/4745 , A61K31/498 , A61K31/5377 , A61K31/538 , A61K45/06 , A61K49/00 , C07D241/46 , C07D265/38 , C07D311/84 , C07D311/90 , C07D335/12 , C07D335/14 , C07D335/20 , C07D491/16 , C07D491/22 , C07D493/16 , C09B11/24 , C09B11/28 , C09B17/00 , C09B19/00 , C09B21/00 , C09B57/00 , G01N33/6896 , G01N2800/7047
摘要： This invention pertains generally to processes, uses, methods and materials utilising particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease.
摘要翻译：本发明一般涉及使用特定的呫吨化合物（包括式（I）和（II）的化合物）的方法，用途，方法和材料，如本文进一步定义。这些化合物可用作药物，例如用于治疗tau蛋白病如阿尔茨海默氏病。

3. 发明申请

US20110021510A1 METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) 有权
标题翻译：化学合成和纯化包括氯化亚甲基氯化铵（MTC）的二氨基苯甲酸盐化合物的方法
公开(公告)号：US20110021510A1
公开(公告)日：2011-01-27
申请号：US12875465
申请日：2010-09-03
申请人： John Mervyn David STOREY , James Peter SINCLAIR , Colin MARSHALL , Han Wan TAN , Claude Michel WISCHIK
发明人： John Mervyn David STOREY , James Peter SINCLAIR , Colin MARSHALL , Han Wan TAN , Claude Michel WISCHIK
IPC分类号： A61K31/5415 , C07D279/20 , A01N43/84 , A61P31/12 , A61P33/02 , A61P35/00 , A61P31/14 , A61P31/18 , A61P25/28 , A61P31/04
CPC分类号： A61K31/5415 , A61K9/0019 , A61K49/006 , C07D279/18 , C09B19/02 , G01N33/52 , Y02A50/393
摘要： This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methylhioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.
摘要翻译：本发明一般涉及化学合成和纯化领域，更具体地涉及合成和纯化某些3,7-二氨基 - 吩噻嗪-5-鎓化合物（本文称为“二氨基吩噻嗪鎓化合物”）的方法，包括甲基氯化铑（MTC）（也称为亚甲基蓝）。在一个实施方案中，该方法包括以下步骤：按顺序：亚硝基化（NOS）; 亚硝酰还原（NR）; 硫代磺酸形成（TSAF）; 氧化偶合（OC）; Cr（VI）还原（CR）; 两性离子中间体（IAPOZI）的分离和纯化; 闭环（RC）; 氯化物盐形成（CSF）; 一种：硫化物处理（ST）; 二甲基二硫代氨基甲酸酯处理（DT）; 碳酸盐处理（CT）; 乙二胺四乙酸处理（EDTAT）; 有机萃取（OE）; 和重结晶（RX）。本发明还涉及所得的（高纯度）化合物，包含它们的组合物（例如片剂，胶囊）及其在灭活病原体的方法中的用途，以及治疗和诊断方法等，例如对于tau蛋白病，阿尔茨海默病（AD），皮肤癌，黑素瘤，病毒性疾病，细菌性疾病或原生动物疾病。

4. 发明授权

US07335652B2 Neurofibrillary labels 有权
标题翻译：神经原纤维标签
公开(公告)号：US07335652B2
公开(公告)日：2008-02-26
申请号：US10665008
申请日：2003-09-22
申请人： Claude Michel Wischik , Charles Robert Harrington , Janet Elizabeth Rickard , David Horsley
发明人： Claude Michel Wischik , Charles Robert Harrington , Janet Elizabeth Rickard , David Horsley
IPC分类号： A61K31/54
CPC分类号： C07D417/12 , C07D277/66 , C07D279/20 , G01N33/583 , G01N33/6896
摘要： Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, by (i) introducing into the subject a ligand capable of labeling aggregated paired helical filament (PHF) tau protein, (ii) determining the presence and/or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. The methods can be used for pre-mortem diagnosis and staging of tauopathies such as Alzheimer's Disease. Preferred ligands include sulphonated-benzothiazole-like compounds and diaminophenothiazines.
摘要翻译：公开了用于确定被认为患有疾病的受试者中与tau蛋白病相关的神经原纤维变性的阶段的方法，方法是（i）向受试者引入能够标记聚集的成对螺旋丝（PHF）tau蛋白的配体，（ii）确定与受试者的脑内侧颞叶结合的细胞外聚集的PHF tau的配体的存在和/或量的量，（iii）将（ii）中确定的测定结果与受试者的神经原纤维变性程度相关联。这些方法可用于妊娠前诊断和分期的阿尔茨海默病等tau蛋白病。优选的配体包括磺化苯并噻唑类化合物和二氨基吩噻嗪。

5. 发明授权

US06953794B2 Inhibition of tau-tau association 失效
标题翻译：抑制tau-tau结合
公开(公告)号：US06953794B2
公开(公告)日：2005-10-11
申请号：US10107181
申请日：2002-03-28
申请人： Claude Michel Wischik , Patricia Carol Edwards , Charles Robert Harrington , Martin Roth , Aaron Klug
发明人： Claude Michel Wischik , Patricia Carol Edwards , Charles Robert Harrington , Martin Roth , Aaron Klug
IPC分类号： G01N33/53 , A61K31/54 , A61K31/5415 , A61P25/28 , C07D279/20 , C07K14/47 , G01N33/15 , G01N33/50 , G01N33/531 , G01N33/543 , G01N33/566 , G01N33/68
CPC分类号： G01N33/502 , A61K31/54 , A61K31/5415 , C07K14/4711 , G01N33/5008 , G01N33/5058 , G01N33/6896 , G01N2333/4709 , G01N2500/00 , G01N2800/28 , G01N2800/2821
摘要： A composition and use thereof for the prophylaxis or treatment of Alzheimer's disease, motor neurone disease, Lewy body disease, Pick's disease or progressive supranuclear palsy. The composition includes an agent which modulates or inhibits tau-tau association and which does not inhibit tau-tubulin binding. In the method the agent is administered to an individual in order to achieve the desired therapeutic effect. Preferably the agent which is administered is a phenothiazine compound.
摘要翻译：用于预防或治疗阿尔茨海默病，运动神经元疾病，路易体病，皮克病或进行性核上性麻痹的组合物和用途。组合物包括调节或抑制tau-tau缔合并且不抑制tau蛋白结合的药剂。在该方法中，为了获得所需的治疗效果，向个体施用药剂。优选地，施用的药剂是吩噻嗪化合物。

6. 发明申请

US20110294795A1 METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS 有权
标题翻译：二氨基苯甲酸酯化合物的合成和/或纯化方法
公开(公告)号：US20110294795A1
公开(公告)日：2011-12-01
申请号：US13149164
申请日：2011-05-31
申请人： Claude Michel WISCHIK , John Mervyn David Storey , Colin Marshall , James Peter Sinclair , Thomas Craven Baddeley
发明人： Claude Michel WISCHIK , John Mervyn David Storey , Colin Marshall , James Peter Sinclair , Thomas Craven Baddeley
IPC分类号： A61K31/5415 , A61P25/28 , A61P25/16 , A61P35/00 , A61P31/12 , A01P1/00 , A61P33/02 , A61P33/00 , A61P33/06 , A61P31/14 , A61P31/18 , A01N43/84 , C07D279/20 , A61P31/04
CPC分类号： A61K31/5415 , C07D279/18 , C07D279/20
摘要： Described are compositions and methods of making high purity diaminophenothiazinium compounds of the following formula which are characterised by: a purity of greater than 98%; less than 1% Azure B as impurity; less than 0.15% Azure A as impurity; less than 0.15% Azure C as impurity; and less than 0.05% Methylene Violet Bernthsen (MVB) as impurity. Examples include methylthioninium chloride (MTC), also known as Methylene Blue (MB).
摘要翻译：描述了制备下式的高纯度二氨基吩噻嗪鎓化合物的组合物和方法，其特征在于：纯度大于98％; 少于1％的Azure B作为杂质; 小于0.15％的Azure A为杂质; 小于0.15％的Azure C为杂质; 和少于0.05％的亚甲基紫伯氏（MVB）杂质。实例包括甲基硫堇（MTC），也称为亚甲蓝（MB）。

7. 发明授权

US07956183B2 Methods of synthesis and/or purification of diaminophenothiazinium compounds 有权
标题翻译：二氨基吩噻嗪鎓化合物的合成和/或纯化方法
公开(公告)号：US07956183B2
公开(公告)日：2011-06-07
申请号：US12373216
申请日：2007-07-10
申请人： Claude Michel Wischik , John Mervyn David Storey , Colin Marshall , James Peter Sinclair , Thomas Craven Baddeley
发明人： Claude Michel Wischik , John Mervyn David Storey , Colin Marshall , James Peter Sinclair , Thomas Craven Baddeley
IPC分类号： C07D279/28
CPC分类号： A61K31/5415 , C07D279/18 , C07D279/20
摘要： A method for the synthesis of a diaminophenothiazinium compound of the following formula: comprising (a) purifying a corresponding reduced compound which is N-acylated at the heterocyclic nitrogen; (b) deacylating the purified compound to provide the corresponding reduced compound; and (c) oxidizing the reduced compound to provide the diaminophenothiazinium compound. Optional purification may performed, for example, after deacylating and after oxidizing. The method provides high purity diaminophenothiazinium compounds which are suitable for pharmaceutical and related therapeutic uses. Such uses include inactivating pathogens, the treatment of the infectious diseases, and for the treatment of diseases of protein aggregation, such as tauopathies, including Alzheimer's disease.
摘要翻译：一种用于合成下式的二氨基吩噻嗪鎓化合物的方法：包括（a）在杂环氮中纯化相应的N-酰化的还原化合物; （b）将纯化的化合物去酰化以提供相应的还原化合物; 和（c）氧化还原的化合物以提供二氨基吩噻嗪鎓化合物。任选的纯化可以例如在脱酰基后和氧化后进行。该方法提供了适用于药物和相关治疗用途的高纯度二氨基吩噻嗪鎓化合物。这样的用途包括灭活病原体，感染性疾病的治疗以及治疗蛋白质聚集的疾病，诸如包括阿尔茨海默病在内的tau蛋白病。

8. 发明授权

US07834237B2 Materials and methods relating to protein aggregation in neurodegenerative disease 有权
标题翻译：与神经退行性疾病中的蛋白质聚集相关的材料和方法
公开(公告)号：US07834237B2
公开(公告)日：2010-11-16
申请号：US10451367
申请日：2002-01-02
申请人： Claude Michel Wischik , Janet Elizabeth Rickard , David Horsley , Charles Robert Harrington , Franz Theuring , Karsten Stamer , Claudia Zabke
发明人： Claude Michel Wischik , Janet Elizabeth Rickard , David Horsley , Charles Robert Harrington , Franz Theuring , Karsten Stamer , Claudia Zabke
IPC分类号： G01N33/00 , A01K67/00 , A01K67/033 , A01K67/027 , C12N15/00
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/20 , A01K2227/105 , A01K2267/0312 , A01K2267/0318 , C07K14/4711 , C07K2319/00 , G01N33/6896 , G01N2500/00
摘要： Disclosed is a method of inducing or modeling a disease associated with pathological tau protein aggregation. The method can be carried out in vitro and animal models, and may be used to screen for therapeutic, prognostic or diagnostic agents.
摘要翻译：公开了诱导或模拟与病理性tau蛋白聚集相关的疾病的方法。该方法可以在体外和动物模型中进行，并且可以用于筛选治疗，预后或诊断剂。

9. 发明申请

US20100285605A1 Neurofibrillary labels 有权
标题翻译：神经原纤维标签
公开(公告)号：US20100285605A1
公开(公告)日：2010-11-11
申请号：US12662887
申请日：2010-05-10
申请人： Claude Michel Wischik , Charles Robert Harrington , Janet Elizabeth Rickard , David Horsley
发明人： Claude Michel Wischik , Charles Robert Harrington , Janet Elizabeth Rickard , David Horsley
IPC分类号： G01N33/566
CPC分类号： C07D417/12 , C07D277/66 , C07D279/20 , G01N33/583 , G01N33/6896
摘要： Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, which methods comprise the steps of: (i) introducing into the subject a ligand capable of labelling aggregated paired helical filament (PHF) tau protein, (ii) determining the presence and\or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. The methods can be used for pre-mortem diagnosis and staging of tauopathies such as Alzheimer's Disease. Preferred ligands include sulphonated-benzothiazole-like compounds and diaminophenothiazines. Novel ligands (e.g. sulphonated-benzothiazole-like compounds) are also provided. The method may also include the use of “blocking ligands” to block competing binding sites. In other aspects the invention provides in vitro methods for identifying ligands capable of labeling aggregated PHF tau protein, the methods comprising the steps of: (i) providing a first agent suspected of being capable of labeling aggregated PHF tau protein, (ii) contacting (a) a tau protein or a derivative thereof containing the tau core fragment bound to a solid phase so as to expose a high affinity tau capture site, with (b) a liquid phase tau protein or derivative thereof capable of binding to the solid phase tau protein or derivative, and (c) said selected first agent and (d) a second agent known to be tau-tau binding inhibitor, (iii) selecting first agent which fully or partially relieves the inhibition of binding of the liquid phase tau protein or derivative of (b) to the solid phase tau protein or derivative of (a) by the inhibitor (d). Ligands may also be tested to confirm that they are not themselves inhibitors.
摘要翻译：公开了用于确定被认为患有疾病的受试者中与tau蛋白病相关的神经原纤维变性的阶段的方法，该方法包括以下步骤：（i）将能够标记聚集的成对螺旋丝（PHF）的配体引入受试者， tau蛋白，（ii）确定与受试者的脑内侧颞叶中细胞外聚集的PHF tau结合的配体的存在和/或量，（iii）将（ii）中确定的测定结果与的神经原纤维变性。这些方法可用于妊娠前诊断和分期的阿尔茨海默病等tau蛋白病。优选的配体包括磺化苯并噻唑类化合物和二氨基吩噻嗪。还提供了新的配体（例如磺化的苯并噻唑类化合物）。该方法还可以包括使用“阻断配体”来阻止竞争结合位点。在其它方面，本发明提供了用于鉴定能够标记聚集的PHF tau蛋白的配体的体外方法，所述方法包括以下步骤：（i）提供疑似能够标记聚集的PHF tau蛋白的第一药剂，（ii） a）包含与固相结合的tau核心片段的tau蛋白或其衍生物，以暴露高亲和力tau捕获位点，（b）能够结合固相tau的液相tau蛋白或其衍生物蛋白质或衍生物，和（c）所述选择的第一试剂和（d）已知为tau-tau结合抑制剂的第二药剂，（iii）选择完全或部分缓解液相tau蛋白结合抑制的第一药剂，或（b）衍生物与固相tau蛋白或（a）的抑制剂（d）的衍生物。也可以测试配体以确认它们本身不是抑制剂。

10. 发明申请

US20090259040A1 METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS 有权
标题翻译：二氨基苯甲酸酯化合物的合成和/或纯化方法
公开(公告)号：US20090259040A1
公开(公告)日：2009-10-15
申请号：US12373216
申请日：2007-07-10
申请人： Claude Michel Wischik , John Mervyn David Storey , Colin Marshall , James Peter Sinclair , Thomas Craven Baddeley
发明人： Claude Michel Wischik , John Mervyn David Storey , Colin Marshall , James Peter Sinclair , Thomas Craven Baddeley
IPC分类号： C07D279/18
CPC分类号： A61K31/5415 , C07D279/18 , C07D279/20
摘要： This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesis and/or purification of certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis, etc., for example, a tauopathy; a disease of tau protein aggregation; Alzheimer's disease (AD); Pick's disease; Progressive Supranuclear Palsy (PSP); fronto temporal dementia (FTD); parkinsonism linked to chromosome 17 (FTDP-17); disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC); pallido-ponto-nigral degeneration (PPND); Guam-ALS syndrome; pallido-nigro-luysian degeneration (PNLD); cortico-basal degeneration (CBD); mild cognitive impairment (MCI); skin cancer; melanoma; methemoglobinemia; a viral infection; a bacterial infection; a protozoal infection; a parasitic infection; malaria; visceral leishmaniasis; African sleeping sickness; toxoplasmosis; giardiasis; Chagas' disease; Hepatitis C virus (HCV) infection; human immunodeficiency virus (HIV) infection; West Nile virus (WNV) infection; a synucleinopathy; Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); drug-induced parkinsonism; and pure autonomic failure (PAF).
摘要翻译：本发明一般涉及化学合成和纯化领域，更具体地涉及合成和/或纯化某些3,7-二氨基吩噻嗪-5-肟化合物（本文称为“二氨基吩噻嗪鎓化合物”）的方法，包括甲基硫堇（MTC）（也称为亚甲蓝）。本发明还涉及所得的（高纯度）化合物，包含它们的组合物（例如片剂，胶囊）及其在灭活病原体的方法中的用途，以及医学治疗，预防和诊断等方法，tau病 tau蛋白聚集的疾病; 阿尔茨海默病（AD）; 皮克病进行性核核麻痹（PSP）颞痴呆（FTD）; 与17号染色体相关的帕金森综合征（FTDP-17）; 去抑痴呆 - 帕金森综合征 - 肌萎缩综合征（DDPAC）; 苍白球 - 黑质变性（PPND）; 关岛ALS综合征苍白球黑素瘤变性（PNLD）; 皮质基底变性（CBD）; 轻度认知障碍（MCI）; 皮肤癌; 黑色素瘤高铁血红蛋白血症; 病毒感染; 细菌感染; 原生动物感染; 寄生虫感染; 疟疾; 内脏利什曼病非洲昏睡病弓形体病贾第虫病恰加斯病丙型肝炎病毒（HCV）感染; 人类免疫缺陷病毒（HIV）感染; 西尼罗病毒（WNV）感染; 突触核蛋白病帕金森病（PD）; 路易体痴呆（DLB）; 多系统萎缩（MSA）; 药物引起的帕金森综合征和纯自主神经衰竭（PAF）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式